#USA #San Diego #Acute Myeloid Leukemia #CAR-NK #Precision Biologics

Precision Biologics Unveils Novel Target for CAR-NK in AML at AACR 2026

On April 19, 2026, Precision Biologics, Inc. will present pioneering research at the American Association for Cancer Research (AACR) Annual Meeting held in San Diego, California. The focus will be on a novel target in Acute Myeloid Leukemia (AML), aiming to enhance the effectiveness of CAR-NK cell therapies. The study showcases groundbreaking data regarding truncated Core 1 O-glycans, which are expressed across several human AML subtypes, indicating a significant advancement in AML treatment options.

The research, entitled "NEO-201-recognized truncated Core 1 O-glycans represent a new target for CAR-NK therapy in AML," aims to address the ongoing challenges faced in AML treatments, notably the scarcity of antigens that selectively target leukemic cells while sparing healthy hematopoietic stem cells. Data to be shared at the conference shows that the antigen identified by NEO-201 is predominantly absent in early hematopoietic progenitors, making it a promising target for therapies directed at refractory leukemias.

Dr. Philip M. Arlen, the CEO of Precision Biologics, expressed enthusiasm about the discovery, stating, "Our findings were unexpected as this novel target was initially discovered in solid tumors, yet it demonstrates expression in hematologic cancers as well. This opens new avenues for targeting specific glycans in developing cellular therapies for difficult-to-treat leukemias."

The urgency of such advancements cannot be overstated. Recent statistics indicate that acute myeloid leukemia has a grim five-year relative survival rate of only 32.9% from 2015 to 2021. This is particularly alarming considering that the disease accounted for approximately 22,000 new cases in the U.S. in 2025 alone, resulting in over 11,000 deaths.

At the AACR Annual Meeting, Precision Biologics will showcase its findings during a poster session scheduled for April 19, from 2 PM to 5 PM PT at the San Diego Convention Center. The session falls under the immunology category, focusing on alternative cell types and in situ cell therapies. The poster will be located at Section 7, Board Number 7, with the abstract published in the journal Cancer Research, allowing for greater audience engagement and discussion.

Precision Biologics, founded in 2012, specializes in developing therapeutic and diagnostic solutions aimed at both detecting and treating cancer. Their innovative approach to antibody drug candidates focuses on targeting tumors with minimal collateral damage to surrounding healthy tissues. By fusing cutting-edge technologies with their proprietary cancer vaccines, the company is poised to create transformative treatments that considerably impact cancer detection and therapy.

For more information and updates on their findings, visit Precision Biologics. The upcoming presentation at AACR 2026 stands as a crucial step forward in the battle against AML, promising hope to thousands affected by this challenging disease.